Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes.
Chronic kidney disease
Combination therapy
Finerenone
Glucagon-like peptide-1 receptor agonist
Sodium-glucose cotransporter-2 inhibitor
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
08
02
2024
accepted:
24
06
2024
medline:
2
8
2024
pubmed:
2
8
2024
entrez:
1
8
2024
Statut:
epublish
Résumé
Given the substantial burden of chronic kidney disease associated with type 2 diabetes, an aggressive approach to treatment is required. Despite the benefits of guideline-directed therapy, there remains a high residual risk of continuing progression of chronic kidney disease and of cardiovascular events. Historically, a linear approach to pharmacologic management of chronic kidney disease has been used, in which drugs are added, then adjusted, optimized, or stopped in a stepwise manner based on their efficacy, toxicity, effects on a patient's quality of life, and cost. However, there are disadvantages to this approach, which may result in missing a window of opportunity to slow chronic kidney disease progression. Instead, a pillar approach has been proposed to enable earlier treatment that simultaneously targets multiple pathways involved in disease progression. Combination therapy in patients with chronic kidney disease associated with type 2 diabetes is being investigated in several clinical trials. In this article, we discuss current treatment options for patients with chronic kidney disease associated with type 2 diabetes and provide a rationale for tailored combinations of therapies with complementary mechanisms of action to optimize therapy using a pillar-based treatment strategy. [This article includes a plain language summary as an additional file].
Identifiants
pubmed: 39090593
doi: 10.1186/s12882-024-03652-5
pii: 10.1186/s12882-024-03652-5
doi:
Substances chimiques
Hypoglycemic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
248Informations de copyright
© 2024. The Author(s).
Références
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022 Kidney Int Suppl (2011), 2022. 12(1): pp. 7–11.
United States Renal Data System (USRDS). 2022 Annual Data Report. Chronic Kidney Disease: Chap. 1: CKD in the General Population. 2022 09/06/2023]; https://usrds-adr.niddk.nih.gov/2022/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd .
Kdoqi. KDOQI Clinical Practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–154.
Afkarian M, et al. Diabetes, kidney disease, and cardiovascular outcomes in the Jackson Heart Study. Clin J Am Soc Nephrol. 2016;11(8):1384–91.
pubmed: 27340284
pmcid: 4974894
doi: 10.2215/CJN.13111215
Li H, et al. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from global burden of Disease 2017. J Diabetes Investig. 2021;12(3):346–56.
pubmed: 32654341
doi: 10.1111/jdi.13355
CKDWG, Kidney Disease: Improving Global Outcomes. KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117–314.
Mullins CD, et al. CKD progression and economic burden in individuals with CKD associated with type 2 diabetes. Kidney Med. 2022;4(11):100532.
pubmed: 36339666
pmcid: 9630787
doi: 10.1016/j.xkme.2022.100532
United States Renal Data System (USRDS). 2022 Annual data report. Chronic Kidney Disease: Chap. 6: Healthcare Expenditures for Persons with CKD. 2022 November 6, 2023]; https://usrds-adr.niddk.nih.gov/2022/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd .
United States Renal Data System (USRDS). 2022 Annual data report. End Stage Renal Disease: Chap. 9: Healthcare Expenditures for Persons with ESRD. 2022 November 6, 2023]; https://usrds-adr.niddk.nih.gov/2022/end-stage-renal-disease/9-healthcare-expenditures-for-persons-with-esrd .
McGill JB, et al. Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria. BMJ Open Diabetes Res Care. 2022;10(4):e002806.
pubmed: 35790319
pmcid: 9258490
doi: 10.1136/bmjdrc-2022-002806
Chaudhuri A, Ghanim H, Arora P. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes Obes Metab. 2022;24(3):365–76.
pubmed: 34779091
doi: 10.1111/dom.14601
Bakris GL, et al. Effect of Finerenone on chronic kidney Disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–29.
pubmed: 33264825
doi: 10.1056/NEJMoa2025845
Pitt B, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–63.
pubmed: 34449181
doi: 10.1056/NEJMoa2110956
Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.
pubmed: 30990260
doi: 10.1056/NEJMoa1811744
Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.
pubmed: 32970396
doi: 10.1056/NEJMoa2024816
The EMPA-Kidney Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–27.
doi: 10.1056/NEJMoa2204233
Naaman SC, Bakris GL. Diabetic Nephropathy: Update on pillars of Therapy slowing progression. Diabetes Care. 2023;46(9):1574–86.
pubmed: 37625003
doi: 10.2337/dci23-0030
Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in chronic kidney disease. Kidney Int. 2022;102(5S):S1–127.
de Boer IH, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Kidney Int. 2022;102(5):974–89.
pubmed: 36202661
doi: 10.1016/j.kint.2022.08.012
American Diabetes Association Professional Practice. 11. Chronic kidney Disease and Risk Management: standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S219–30.
doi: 10.2337/dc24-S011
US Food and Drug Administration. Farxiga (dapagaflozin) Prescribing Information. 2023 August 30, 2023]; https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202293s026lbl.pdf .
US Food and Drug Administration. Invokana (canagliflozin) Prescribing Information. 2023 August 30, 2023]; https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204042s034lbl.pdf .
US Food and Drug Adminstration. Jardiance (empagliflozin) Prescribing Information. 2023 November 15, 2023]; https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204629s033lbl.pdf .
US Food and Drug Administration. Victoza (liraglutide) Prescribing Information. 2023 August 30, 2023]; https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf .
US Food and Drug Administration. Ozempic (semaglutide) Prescribing Information. 2022 August 30, 2023]; https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf .
US Food and Drug Administration. Trulicity (dulaglutide) Prescribing Information. 2022 August 30, 2023]; https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s036lbl.pdf .
Gerstein HC, et al. Cardiovascular and renal outcomes with Efpeglenatide in Type 2 diabetes. N Engl J Med. 2021;385(10):896–907.
pubmed: 34215025
doi: 10.1056/NEJMoa2108269
Perkovic V et al. Effects of Semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med, 2024.
US Food and Drug Administration. Kerendia (finerenone) Prescribing Information. 2022 August 30, 2023]; https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf .
Tuttle KR, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet. 2024;403(10424):379–90.
pubmed: 38109916
doi: 10.1016/S0140-6736(23)02408-X
Smeijer JD, et al. Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease. Cardiovasc Diabetol. 2023;22(1):251.
pubmed: 37716952
pmcid: 10505320
doi: 10.1186/s12933-023-01964-8
Grune J, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone’s antifibrotic activity. Hypertension. 2018;71(4):599–608.
pubmed: 29437893
doi: 10.1161/HYPERTENSIONAHA.117.10360
Kolkhof P, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69–78.
pubmed: 24621652
doi: 10.1097/FJC.0000000000000091
Rossing P, et al. Finerenone in Predominantly Advanced CKD and Type 2 diabetes with or without sodium-glucose Cotransporter-2 inhibitor therapy. Kidney Int Rep. 2022;7(1):36–45.
pubmed: 35005312
doi: 10.1016/j.ekir.2021.10.008
Rossing P, et al. Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial. Diabetes Obes Metab. 2022;24(1):125–34.
pubmed: 34580995
doi: 10.1111/dom.14558
Marso SP, et al. Liraglutide and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
pubmed: 27295427
pmcid: 4985288
doi: 10.1056/NEJMoa1603827
Marso SP, et al. Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
pubmed: 27633186
doi: 10.1056/NEJMoa1607141
Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.
pubmed: 31189511
doi: 10.1016/S0140-6736(19)31149-3
Morales J, et al. Perspectives on chronic kidney disease with type 2 diabetes and risk management: practical viewpoints and a paradigm shift using a pillar approach. Clin Diabetes. 2023;41(4):553–66.
pubmed: 37849516
pmcid: 10577512
doi: 10.2337/cd22-0110
Holtkamp FA, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80(3):282–7.
pubmed: 21451458
doi: 10.1038/ki.2011.79
Drion I, et al. Clinical evaluation of analytical variations in serum creatinine measurements: why laboratories should abandon Jaffe techniques. BMC Nephrol. 2012;13:133.
pubmed: 23043743
pmcid: 3504563
doi: 10.1186/1471-2369-13-133
Delanaye P, et al. An age-calibrated definition of chronic kidney disease: rationale and benefits. Clin Biochem Rev. 2016;37(1):17–26.
pubmed: 27057075
pmcid: 4810758
Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the management of Heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation. 2022;145(18):e895–1032.
pubmed: 35363499
American Diabetes Association Professional Practice. 10. Cardiovascular Disease and Risk Management: standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S179–218.
doi: 10.2337/dc24-S010
Provenzano M, et al. The kidney protective effects of the sodium-glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists. Kidney Int Rep. 2022;7(3):436–43.
pubmed: 35257056
doi: 10.1016/j.ekir.2021.12.013
Meraz-Muñoz AY, Weinstein J, Wald R. eGFR decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined. Kidney360, 2021. 2(6): p. 1042–7.
Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685–93.
pubmed: 10724055
doi: 10.1001/archinte.160.5.685
Ohkuma T, et al. Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus. Hypertension. 2019;73(1):84–91.
pubmed: 30571562
doi: 10.1161/HYPERTENSIONAHA.118.12060
Agarwal R, et al. Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022;33(1):225–37.
pubmed: 34732509
pmcid: 8763180
doi: 10.1681/ASN.2021070942
Neuen BL, et al. Estimated Lifetime Cardiovascular, kidney, and Mortality benefits of Combination Treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with Conventional Care in patients with type 2 diabetes and Albuminuria. Circulation. 2024;149(6):450–62.
pubmed: 37952217
doi: 10.1161/CIRCULATIONAHA.123.067584
Kim D, Perkovic V, Kotwal S. Barriers to care: New medications and CKD. Kidney Int Rep. 2024;9(3):504–7.
pubmed: 38481511
doi: 10.1016/j.ekir.2023.12.012
Rifkin DE, et al. Medication adherence behavior and priorities among older adults with CKD: a semistructured interview study. Am J Kidney Dis. 2010;56(3):439–46.
pubmed: 20674113
pmcid: 2935303
doi: 10.1053/j.ajkd.2010.04.021
Mechta Nielsen T, et al. Adherence to medication in patients with chronic kidney disease: a systematic review of qualitative research. Clin Kidney J. 2018;11(4):513–27.
pubmed: 30094015
doi: 10.1093/ckj/sfx140
Moranne O, et al. Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol. 2013;8(10):1694–701.
pubmed: 23929924
pmcid: 3789346
doi: 10.2215/CJN.06960712
Humphrey T, et al. How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies. Clin Kidney J. 2022;15(4):727–37.
pubmed: 35371465
doi: 10.1093/ckj/sfab243
Riccio E, et al. RAAS inhibitor prescription and hyperkalemia event in patients with chronic kidney disease: a single-center retrospective study. Front Cardiovasc Med. 2022;9:824095.
pubmed: 35224054
pmcid: 8874323
doi: 10.3389/fcvm.2022.824095
Fried LF, et al. ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease. Am J Manag Care. 2021;27(20 Suppl):S360–8.
pubmed: 34878753
Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709–17.
pubmed: 10471456
doi: 10.1056/NEJM199909023411001
Pitt B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.
pubmed: 12668699
doi: 10.1056/NEJMoa030207
US Food and Drug Administration. Aldactone (spironolactone) Prescribing Information. 2018 April 8, 2024].
US Food and Drug Administration. Inspra (eplerenone) Prescribing Information. 2016 April 8, 2024].
Selvaraj S, et al. Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction. Circ Heart Fail. 2018;11(11):e005288.
pubmed: 30571191
pmcid: 6594383
doi: 10.1161/CIRCHEARTFAILURE.118.005288
Brandt-Jacobsen NH, et al. Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: data from the MIRAD trial. Diabetes Metab. 2021;47(4):101190.
pubmed: 32919068
doi: 10.1016/j.diabet.2020.08.005
Vardeny O, et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC Heart Fail. 2019;7(12):1022–8.
pubmed: 31779923
doi: 10.1016/j.jchf.2019.08.019
Agarwal R, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152–61.
pubmed: 33099609
doi: 10.1093/eurheartj/ehaa736
Agarwal R, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474–84.
pubmed: 35023547
doi: 10.1093/eurheartj/ehab777
Goyal A, Cusick A, Thielemier. B. ACE inhibitors. StatPearls. 2023 September 7, 2023]; https://www.ncbi.nlm.nih.gov/books/NBK430896/ .
Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585–92.
pubmed: 15295051
doi: 10.1056/NEJMra035279
Slagman MC, Navis G, Laverman GD. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease. Curr Opin Nephrol Hypertens. 2010;19(2):140–52.
pubmed: 20051849
doi: 10.1097/MNH.0b013e3283361887
AlQudah M, Hale TM, Czubryt MP. Targeting the renin-angiotensin-aldosterone system in fibrosis. Matrix Biol. 2020;91–92:92–108.
pubmed: 32422329
pmcid: 7434656
doi: 10.1016/j.matbio.2020.04.005
Campbell KN, Raij L, Mundel P. Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes. Curr Diabetes Rev. 2011;7(1):3–7.
pubmed: 21067505
pmcid: 3690294
doi: 10.2174/157339911794273973
Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.
pubmed: 11565518
doi: 10.1056/NEJMoa011161
Lewis EJ, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–60.
pubmed: 11565517
doi: 10.1056/NEJMoa011303
Lerma EV, Wilson DJ. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Expert Rev Clin Pharmacol. 2022;15(5):501–13.
pubmed: 35762406
doi: 10.1080/17512433.2022.2094770
Agarwal R, et al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transpl. 2022;37(6):1014–23.
doi: 10.1093/ndt/gfaa294
Amazit L, et al. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem. 2015;290(36):21876–89.
pubmed: 26203193
pmcid: 4571943
doi: 10.1074/jbc.M115.657957
Grune J, et al. Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol. 2016;67(5):402–11.
pubmed: 26859196
doi: 10.1097/FJC.0000000000000366
Luo X, et al. Influence of SGLT2i and RAASi and their combination on risk of hyperkalemia in DKD: a network meta-analysis. Clin J Am Soc Nephrol. 2023;18(8):1019–30.
pubmed: 37256921
doi: 10.2215/CJN.0000000000000205
Scholtes RA, et al. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. Diabetes Care. 2021;44(2):440–7.
pubmed: 33318125
doi: 10.2337/dc20-2604
Lambers Heerspink HJ, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–62.
pubmed: 23668478
doi: 10.1111/dom.12127
Lawler PR, et al. Changes in cardiovascular biomarkers associated with the sodium-glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin in patients with chronic kidney disease and type 2 diabetes. Diabetes Care. 2021;44(3):e45–7.
pubmed: 33436398
doi: 10.2337/dc20-2265
Tsukamoto S, et al. Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2022;194:110161.
pubmed: 36403681
doi: 10.1016/j.diabres.2022.110161
Bjune T, et al. Hyperkalemia and the use of new potassium binders a single center experience from Vestfold Norway (the PotBind Study). Int J Nephrol Renovasc Dis. 2023;16:73–82.
pubmed: 36960344
pmcid: 10027611
doi: 10.2147/IJNRD.S401623
Blonde L, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: developing a diabetes mellitus comprehensive care plan–2022 update. Endocr Pract. 2022;28(10):923–1049.
pubmed: 35963508
pmcid: 10200071
doi: 10.1016/j.eprac.2022.08.002
Greenwalt L. IQVIA: Inequalities in Access to Treatment for Type 2 Diabetes Patients with Chronic Kidney Disease. 2022 8 April, 2024].
Schernthaner G, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19(1):185.
pubmed: 33097060
pmcid: 7585305
doi: 10.1186/s12933-020-01154-w
Desai NR, et al. Design and rationale of FINE-REAL: a prospective study of finerenone in clinical practice. J Diabetes Complications. 2023;37(4):108411.
pubmed: 36857997
doi: 10.1016/j.jdiacomp.2023.108411
Heerspink HJ, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752–72.
pubmed: 27470878
doi: 10.1161/CIRCULATIONAHA.116.021887
Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215–25.
pubmed: 27878313
doi: 10.1007/s00125-016-4157-3
Umanath K, Lewis JB. Update on Diabetic Nephropathy: Core Curriculum 2018. Am J Kidney Dis. 2018;71(6):884–95.
pubmed: 29398179
doi: 10.1053/j.ajkd.2017.10.026
de Simoes F, et al. Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) cross-sectional study. Cureus. 2023;15(1):e33509.
Nanna MG, et al. Use of sodium-glucose cotransporter 2 inhibitors and glucagonlike peptide-1 receptor agonists in patients with diabetes and cardiovascular disease in community practice. JAMA Cardiol. 2023;8(1):89–95.
pubmed: 36322056
doi: 10.1001/jamacardio.2022.3839
Jeong SJ, et al. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study. BMC Nephrol. 2021;22(1):177.
pubmed: 33990175
pmcid: 8122538
doi: 10.1186/s12882-021-02381-3
Fehse F, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005;90(11):5991–7.
pubmed: 16144950
doi: 10.1210/jc.2005-1093
Maselli DB, Camilleri M. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol. 2021;1307:171–92.
pubmed: 32077010
doi: 10.1007/5584_2020_496
van Bloemendaal L, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63(12):4186–96.
pubmed: 25071023
doi: 10.2337/db14-0849
Vilsboll T, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
pubmed: 22236411
pmcid: 3256253
doi: 10.1136/bmj.d7771
Nguyen A, et al. Association between obesity and chronic kidney disease: multivariable mendelian randomization analysis and observational data from a bariatric surgery cohort. Diabetes. 2023;72(4):496–510.
pubmed: 36657976
pmcid: 10197093
doi: 10.2337/db22-0696
Zelniker TA, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022–31.
pubmed: 30786725
doi: 10.1161/CIRCULATIONAHA.118.038868
Li J, et al. Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease. Clin J Am Soc Nephrol. 2020;15(11):1678–88.
pubmed: 32518100
pmcid: 7646234
doi: 10.2215/CJN.02690320